Strategic Cooperation Framework Agreement With Chicmax In Relation To KT-939
Suzhou, 17 March, 2026-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that Suzhou Kintor Pharmaceuticals, Inc. ( “Suzhou Kintor”), a wholly-owned subsidiary of the Company, entered into the exclusive strategic cooperation framework agreement (the “Framework Agreement”) in the cosmetics sector with Shanghai Chicmax Cosmetic Co., Ltd. (a company listed on The Stock Exchange of Hong Kong Limited (stock code: 2145), “Chicmax”) in relation to the rapid commercialization of the Company’s whitening and freckle-removing functional cosmetic raw material KT-939.
Chicmax, a multi-brand beauty company listed on The Stock Exchange of Hong Kong Limited (stock code: 2145), focuses on research and development, manufacturing and sales of mass skin care, maternal, baby & teenagers skin care, cleansing and personal care, makeup, dermocosmetics and premium skin care.
With an operational history of more than 20 years, Chicmax has cultivated solid independent R&D capabilities and garnered comprehensive experience in multi-brand development and operations within China’s cosmetics industry, with strong dual R&D capabilities and talents, combined with an extensive and dynamic sales and distribution network. Its dedication to continuous innovation in marketing strategies, robust brand power, exceptional supply chain management, and experienced team has enabled it to successfully create a diverse array of popular cosmetics brands, including multiple well-known brands such as KANS, newpage, ARMIYO, and Baby Elephant.
Pursuant to the Framework Agreement, Suzhou Kintor and Chicmax will exclusively collaborate in the cosmetics sector on the registration of KT-939 as a new cosmetic ingredient and the registration of cosmetic products with KT-939 as the main ingredient, and jointly conduct the R&D and customization of functional raw materials with an aim to position KT-939 as the "ultimate domestic whitening agent" with prominent industry influence.
The exclusive Framework Agreement in the cosmetics sector with Chicmax is based on the high complementarity of resources and strategic synergy to each other in the cosmetics and biopharmaceutical fields, aiming to fully leverage the premium resources and capabilities of both parties to jointly explore the market and realize win-win values.
As an R&D-driven leader in the multi-brand cosmetics industry, Chicmax possesses strong brand operation and market commercialization capabilities. Suzhou Kintor, with its core focus on innovative drug research and development, has built a solid foundation in raw material research and development and technological expertise. Through this collaboration, both parties will not only accelerate the commercialization process of KT-939, enabling the simultaneous launch of the cosmetic ingredient and products, but also foster synergies in technology sharing, intellectual property protection, and market promotion. This will further enhance the technological sophistication and market competitiveness of domestic whitening ingredients, ultimately achieving the strategic goals of mutual benefits and development.
About Kintor Pharmaceutical Limited
Founded in 2009, Kintor Pharmaceutical Limited focuses on developing and commercializing potential "first-in-class" and "best-in-class" innovative drugs and functional cosmetics, aiming to be a leading enterprise in such areas, and establish a “troika” business model formed by R&D business of innovative topical drugs, B2B business of functional cosmetic raw materials and B2C business of functional cosmetic products. After several years' development, the Company has developed diverse product pipeline built on dermatology related diseases. The products cover diseases with high incidence rate globally and extend to functional cosmetics, which can meet the needs of clinical dermatology and cosmetics consumers worldwide. Kintor Pharma's layout includes innovative small molecule and biologic drugs, consisting of five productsunder clinical development and several preclinical research programs. Kintor Pharma has been granted more than 100 patents worldwide. On 22 May 2020, Kintor Pharma was officially listed on the Hong Kong Stock Exchange with the stock code 9939.HK. For more information, please visit www.kintor.com.cn.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
